Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR mutant Lung Cancer

Irreversible pyrimidine based EGFR inhibitors, including WZ4002, selectively inhibit both EGFR activating and EGFR inhibitor resistant T790M mutations more potently than wild type EGFR. While this class of mutant selective EGFR inhibitors is effective clinically in lung cancer patients harboring EGF...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cancer Discov
Egile Nagusiak: Tricker, Erin M., Xu, Chunxiao, Uddin, Sharmeen, Capelletti, Marzia, Ercan, Dalia, Ogino, Atsuko, Pratilas, Christine A., Rosen, Neal, Gray, Nathanael S., Wong, Kwok-Kin, Jänne, Pasi A.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2015
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4824006/
https://ncbi.nlm.nih.gov/pubmed/26036643
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-15-0063
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak